Format

Send to

Choose Destination
Brain Res. 2019 Jun 15;1713:91-101. doi: 10.1016/j.brainres.2018.09.023. Epub 2018 Sep 19.

Dynorphin/kappa-opioid receptor control of dopamine dynamics: Implications for negative affective states and psychiatric disorders.

Author information

1
Synaptic Plasticity Section, Cellular and Neurobiology Research Branch, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD USA; Unit on Neuromodulation and Synaptic Integration, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA. Electronic address: hugo.tejeda@nih.gov.
2
Synaptic Plasticity Section, Cellular and Neurobiology Research Branch, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD USA; Solomon Snyder Neuroscience Department, Johns Hopkins University, Baltimore, MD USA. Electronic address: antonello.bonci@nih.gov.

Abstract

Negative affective states are prevalent symptoms in a plethora of neuropsychiatric disorders, including depression and drug addiction. Dysfunction of mesocorticolimbic dopamine systems has been implicated in negative affective states in neuropsychiatric disorders. The dynorphin/kappa-opioid receptor system is a powerful effector of stress-related behavior and is highly enriched within the mesocorticolimbic dopamine system. Dysfunction of dynorphin/KOR signaling within the mesocorticolimbic dopamine system is implicated in promoting symptoms in neuropsychiatric disorders. As such, the kappa-opioid receptor system provides an important therapeutic target to treat negative affective states associated with psychiatric disorders. In this review, we provide a comprehensive overview of the dynorphin/kappa-opioid receptor system and its role in regulating the mesocorticolimbic dopamine system, motivation, and emotional behavior. Furthermore, we highlight unresolved issues in the field and offer some insights for future research.

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center